D-1055-2020 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-1055-2020 was initiated by Lupin Pharmaceuticals Inc. on March 9, 2020 and is designated Class III. Reason for recall: Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity. The recall status is terminated (terminated May 25, 2021). Affected quantity: 1,712 cartons.

Recall Details

Product Type
Drugs
Report Date
March 18, 2020
Initiation Date
March 9, 2020
Termination Date
May 25, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,712 cartons

Product Description

Bekyree (desogestrel and ethinyl estradiol tablets USP, 0.15 mg/0.02 mg and ethinyl estradiol tablets USP, 0.01 mg), packaged in 1 Wallet of 28 Tablets (NDC 68180-879-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-879-13), Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA.

Reason for Recall

Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity.

Distribution Pattern

Nationwide in the USA and Puerto Rico.

Code Information

Lot #: L800915, Exp July 2020